Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555

R. Upton, P. S. Widdowson, S. Ishii, H. Tanaka, G. Williams

Research output: Contribution to journalArticle

53 Citations (Scopus)


1. We examined the effect of chronic (21 days) oral treatment with the thiazolidinedione, MCC-555 ((±)-5-[{6-(2-fluorbenzyl)-oxy-2-naphy}methyl]-2,4-thiazolidinedione) on metabolic status and insulin sensitivity in obese (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats which display an impaired glucose tolerance (IGT) or overt diabetic symptoms, respectively. 2. MCC-555 treatment to obese Zucker rats (10 and 30 mg kg-1) and diabetic ZDF rats (10 mg kg-1) reduced non-esterified fatty acid concentrations in both rat strains and reduced plasma glucose and triglyceride concentrations in the obese Zucker rats. Liver glycogen concentrations were significantly increased by chronic MCC-555 treatment in both obese Zucker rats (30 mg kg-1 day-1) and diabetic ZDF rats (10 mg kg-1 day-1), as compared with vehicle-treated lean and obese rats and there was a significant increase in hepatic glycogen synthase activity in MCC-555-treated diabetic ZDF rats as compared to vehicle-treated controls. 3. During a euglycaemic hyperinsulinaemic clamp, MCC-555-treated obese Zucker rats and diabetic ZDF rats required significantly higher glucose infusion rates to maintain stable glucose concentrations (2.01 ± 0.19 mg min-1 and 6.42 ± 1.03 mg min-1, respectively) than vehicle-treated obese controls (0.71 ± 0.17 mg min-1 and 2.09 ± 0.71 mg min-1; P < 0.05), demonstrating improved insulin sensitivity in both Zucker and ZDF rats. MCC-555 treatment also enhanced insulin-induced suppression of hepatic glucose production in ZDF rats as measured using infusions of [6-3H]-glucose under clamp conditions. 4. In conclusion, we have demonstrated that MCC-555 improves metabolic status and insulin sensitivity in obese Zucker and diabetic ZDF rats. MCC-555 may prove a useful compound for alleviating the metabolic disturbances and IGT associated with insulin resistance in man.

Original languageEnglish
Pages (from-to)1708-1714
Number of pages7
JournalBritish Journal of Pharmacology
Issue number8
Publication statusPublished - 1998 Dec 1



  • Diabetes
  • MCC-555
  • Metabolism
  • Obese (fa/fa) Zucker rats
  • Thiazolidinedione

ASJC Scopus subject areas

  • Pharmacology

Cite this